OncoMatch/Clinical Trials/NCT04804007
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Is NCT04804007 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Etoposide for germ cell tumor.
Treatment: Etoposide — This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Testicular Germ Cell Tumor
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cisplatin-based combination chemotherapy (cisplatin) — first-line
Relapsed disease after first-line cisplatin-based combination chemotherapy
Must have received: high-dose chemotherapy — salvage
Completed salvage treatment with HDCT and PBSCT for 2 tandem cycles per Institutional Guidelines
Cannot have received: investigational agent
Treatment with any investigational agent within 28 days prior to study registration
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,000 /mcL; Platelets ≥100,000 / mcL; Hemoglobin ≥8 g/dL
Kidney function
Serum creatinine <2mg/dL
Liver function
Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR 5 X ULN for subjects with liver metastases
Adequate organ function lab values obtained within 28 days prior to study registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana University Melvin & Bren Simon Cancer Center · Indianapolis, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify